A5027656786- Sarcoidosis and Beryllium Toxicity Research
- Viral Infections and Immunology Research
- Vasculitis and related conditions
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cardiac Structural Anomalies and Repair
- Eosinophilic Disorders and Syndromes
- Pericarditis and Cardiac Tamponade
- Cardiovascular Effects of Exercise
- Phytoplasmas and Hemiptera pathogens
Helsinki University Hospital
2017-2024
University of Helsinki
2021-2024
Lung Institute
2024
The present study was done to assess the role of sudden cardiac death (SCD) among presenting manifestations and fatalities from sarcoidosis (CS).We analysed altogether 351 cases CS year 1998 through 2015 in Finland. There were 262 patients with a clinical diagnosis treatment CS, 27 an initial lifetime giant cell myocarditis that later converted 62 detected at autopsy identified by screening >820 000 certificates national cause-of-death registry. total case series comprised 253 females 98...
Background: Symptomatic high-grade atrioventricular block (AVB) is the most common and often only presenting manifestation (lone AVB) of cardiac sarcoidosis. Implantation an intracardiac cardioverter defibrillator instead a pacemaker recommended, but true risk fatal arrhythmia, one incident to lone AVB in particular, remains poorly known. Methods: We used Myocardial Inflammatory Diseases Finland Study Group Registry analyze presentations, left ventricular (LV) function, therapy, arrhythmias...
Cardiac sarcoidosis (CS) predisposes to sudden cardiac death (SCD). Guidelines for implantable cardioverter defibrillators (ICDs) in CS have been issued by the Heart Rhythm Society 2014 and American College of Cardiology/American Association/Heart consortium 2017. How well they discriminate high from low risk remains unknown.
Giant cell myocarditis (GCM) is an inflammatory cardiomyopathy akin to cardiac sarcoidosis (CS). We decided study the findings of GCM on magnetic resonance (CMR) imaging and compare with CS.CMR studies 18 patients were analyzed compared CS controls matched for age, sex, left ventricular (LV) ejection fraction presenting manifestations. The analysts blinded clinical data. On admission, duration symptoms (median) was 0.2 months in vs. 2.4 (P = 0.002), troponin T elevated (>50 ng/L) 16/17 2/16...
Background Cardiac sarcoidosis (CS) and giant cell myocarditis (GCM) share many histopathologic clinical features. Whether they are parts of a one‐disease continuum has been discussed. Methods Results We compared medical record data 351 CS 28 GCM cases diagnosed in Finland since the late 1980s followed until February 2018 for composite end point cardiac death, aborted sudden heart transplantation. Heart failure was presenting manifestation 50% versus 15% ( P <0.001), high‐grade...
Abstract Aims Cardiac sarcoidosis (CS) and giant cell myocarditis (GCM) are inflammatory cardiomyopathies sharing histopathological clinical features. Their differentiation is difficult susceptible of confusion apparent mistakes. The possibility that they represent different phenotypes a single disease has been debated. Methods results We made retrospective audit 73 cases GCM diagnosed in Finland since the late 1980s. All available histological material was reanalyzed as were other...
Eosinophilic myocarditis (EM) is a life-threatening acute heart disease. Cardiac magnetic resonance (CMR) excels in the assessment of myocardial diseases but CMR studies EM are limited. We aimed to describe findings histologically proven EM. Patients with seen at an academic center from 2000 through 2020 were identified. Of 28 patients ascertained, 15 had undergone for diagnosis and constitute our study cohort. The patients, aged 51 ± 17 years, presented fever (53%), dyspnea (47%), chest...
BACKGROUND: Cardiac sarcoidosis involves a significant but difficult-to-define risk of sudden cardiac death (SCD). Current guidelines recommend consideration an implantable cardioverter defibrillator for patients with extensive or myocardial late gadolinium enhancement (LGE) on magnetic resonance imaging. However, extensive/significant LGE is not defined. METHODS: A nationwide registry was screened entered before 2020 imaging done <3 months after diagnosis. Available studies were...